

RNS Number : 6862Y
EKF Diagnostics Holdings PLC
28 January 2014

28 January 2014

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Additional Listing

EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, announces that, on 27 January 2014, a former director of the Company exercised options over 225,000 Ordinary Shares of one pence each in the Company (the "Ordinary Shares"), at an exercise price of 18 pence per Ordinary Share.

Application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 225,000 new Ordinary Shares to AIM will become effective on, or around, 3 February 2014. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary shares.

EKF Diagnostics Holdings plc
Paul Foulger, Finance Director

Tel: 029 2071 0570
Mob: 07710 989 255

Canaccord Genuity Limited
Lucy Tilley / Henry Fitzgerald-O'Connor / Julian
Feneley

Tel: 020 7523 8350

Walbrook PR Limited
Paul McManus

Tel: 020 7933 8780
Mob: 07980 541 893 or
paul.mcmanus@walbrookpr.com

Paul Cornelius

Mob: 07866 384 707 or paul.cornelius@walbrookir.com

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS
The company news service from the London Stock Exchange

END

LISPGURGGUPCGPR admin Additional Listing 21443638 A Tue, 01/28/2014 - 12:21 Company
Announcement - General EKF